SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Valuation
CRSP 55.28+5.3%3:59 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Biomaven who wrote (13163)9/28/2004 2:57:50 PM
From: bio_kruncher  Read Replies (1) of 52153
 
re: NABI
we can make educated guesses and calculate some probable p-values.
68 pts / 4 trt groups= about 17 per group.
ways to get 33% are : 5/15, 6/18, 7/21
ways to get 9% are: 1/11, 2/22 (this seems odd)
Chi-square pvalues range from 0.328 to 0.114
I don;t think the 2/22 is a likely outcome for placebo so i'd quess p-value is in the 0.2 - 0.3 range.

OF concern would be lack of disclosure of 'quit rate' for lower dose groups and no mention of antibody results(which was the objective of the study). Interesting results but i think the study is just too small to choose a dose for smoking cessation. Larger Phase II dose ranging still needed.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News